This paper presents three approaches to estimating battery parameters of the electrical equivalent circuit model (ECM) based on electrochemical impedance spectroscopy (EIS); these approaches are referred to as (a) least squares (LS), (b) exhaustive search (ES), and (c) nonlinear least squares (NLS). The ES approach is assisted with the LS method for the rough determination of the lower and upper bound of the ECM parameters, and the NLS approach is incorporated with the Monte Carlo run such that different initial guesses can be assigned to improve the goodness of EIS fitting. The proposed approaches are validated using both simulated and real EIS data. Compared to LS approach, the ES and NLS approaches show better fitting accuracy at various noise levels; whereas both in the validation using simulated EIS data and actual EIS data collected from LG 18650 and Molicel 21700 batteries, the NLS approach shows better fitting accuracy than that of LS and ES approaches. In all cases, compared with the ES approach, the computational time of the NLS approach is significantly faster, and compared with the LS approach, the NLS approach shows a minimal difference in computational time and considerably better fitting performance.

Prostate cancer (PC) is the second most diagnosed cancer among men. It was observed that early diagnosis of disease is highly beneficial for survival of cancer patients. Therefore, extension and increasing quality of life of PC patients can be achieved by broadening the Cancer Screening programs that are aimed at the identification of cancer manifestation in patients at earlier stages before they demonstrate well-understood signs of the disease. Therefore, there is an urgent need in standard, sensitive, robust, and commonly available screening and diagnosis tools for identification of early signs of cancer pathologies. In this respect, “Holy Grail” of cancer researchers and bioengineers for decades have been molecular sensing probes that would allow diagnosis, prognosis, and monitoring of cancer diseases by their interaction with cell-secreted and cellassociated PC biomarkers, e.g. PSA and PSMA correspondinly. At present, most PSA tests are performed at centralized laboratories using high throughput Total PSA immune analyzers which are suitable for dedicated laboratories and are not readily available for the broad health screening. Therefore, the current trend in detection of PC is developments of the portable biosensors for mobile laboratories and individual use. Phage display since its conception by George Smith in 1985 has emerged as a premier tool in molecular biology with widespread applications. This review describes how the paradigm of molecular evolution and phage display revolutionized the methods of early diagnosis and monitoring of PC.